HTGF et al. back HiperScan with €450,000

The fresh funding will be used to enhance the technical development of NIR systems, with a focus on miniaturisation, cost optimisation and scaling of the product. Furthermore, HiperScan plans to globalise its operations and launch its product internationally.

HCS is a new investor in the firm while HTGF first invested in HiperScan in 2009, with a venture funding round of €500,000.

Company
In 2006, HiperScan spun out of Dresdner Fraunhofer Institute for Photonic Microsystems, where the firm worked with innovative scanning-grating technology. HiperScan is still based in Dresden.

So far, the firm has sold 400 of its near-infrared spectroscopes Apo-Ident to German pharmacies. Apo-Ident is used to perform the mandatory identity check of substances used for compounding – the individual creation of pharmaceuticals for a patient's needs. The product was launched in Germany in 2009.

People
Hans-Christian Semmler is managing partner at HCS and will join HiperScan's board. Thomas Tettenborn is investment director of CFH Beteiligungsgesellschaft, which oversees the Technologiegründerfonds Sachsen. Alexander Wolter is CEO of Hiperscan.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Expansion
• Germany
• High-Tech Gründerfonds